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From Trials to Public Health Impact: Transportability of Causal Effects to Inform 
Implementation of HIV Pre-exposure Prophylaxis 
Megha L. Mehrotra 
ABSTRACT 
 With the support of several successful randomized placebo-controlled trials, the FDA 
approved Truvada for daily oral pre-exposure prophylaxis of HIV (PrEP) in the United States in 
2012, and shortly thereafter the CDC and WHO released guidelines for widespread PrEP use 
by all at-risk individuals around the world. However, PrEP rollout is still is infancy, and there are 
several important questions regarding PrEP implementation that cannot be addressed by 
randomized trials. The causal transportability theory developed by Pearl and Bareinboim is a 
mathematically-grounded framework used to consider how effects observed in one setting might 
be applied to another. This dissertation proposes novel ways transportability can be applied to 
improve how trial results are used to inform implementation of PrEP. applies transportability to 
address some of these lingering questions about PrEP implementation.  
 The first chapter uses transportability to better understand why randomization to PrEP 
was effective in preventing HIV among cisgender men but not effective among transgender 
women in the iPrEx study. We find that after transporting the results of the trial from cisgender 
men to transgender women, differences in measured baseline characteristics between the 
populations were sufficient to explain the observed effect heterogeneity in the trial. The second 
chapter demonstrates how transportability can be applied to subgroup analyses of randomized 
controlled trials to produce target-specific guidance for how to most efficiently implement new 
interventions. To illustrate this approach, we transport subgroup analyses of the iPrEx trial to 
two hypothetical target populations and show that the subgroups with the lowest number 
needed to treat differs depending on the composition of the target population. The third and final 
chapter addresses a common practical challenge faced in applying transportability theory to 
real-world data: how to decide which variables to include in a transport estimator. In this 
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chapter, we discuss the various types of unnecessary variables that may inadvertently be 
included in transport estimators. We use a Monte Carlo simulation study to identify what types 
of variables should be included to maximize the performance (with respect to mean-squared 
error) of the parametric g-computation transport estimator.  
 Together these projects highlight how transportability theory can be applied to improve 
translation of study results to real-world populations.  
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INTRODUCTION 
 Results of randomized controlled trials are critically important in the early stages of 
implementing a new intervention. Trial results 1) demonstrate if the intervention was effective, 2) 
highlight which groups it was most effective for, and 3) provide early insight into some potential 
challenges in how an intervention should be implemented. However, trial populations are rarely 
representative of real-world populations planning on implementing a new intervention, and 
differences between populations may affect how useful trial results can be for planning 
implementation. Until recently, this issue of external validity of trial results was an intractable 
problem. However, recent developments in the causal inference literature provide a theoretical 
solution to many of these challenges and can improve the interpretation of trial results for 
broader populations. 
THE TRANSPORTABILITY FRAMEWORK 
Why interventions might vary in effectiveness across different settings is intuitive: if there 
are certain characteristics that modify the effect of an intervention, and the distribution of those 
characteristics varies from setting to setting, then the intervention’s effectiveness would similarly 
vary. Further, if we can measure and account for all the characteristics that both modify the 
effect of the intervention and differ between two settings, then we should be able to predict how 
effective an intervention would be if it were to be implemented in the new setting. 
Transportability formalizes this intuition by building on the theoretical foundations of 
observational causal inference. In doing so, simple modifications of existing tools and statistical 
estimators that are widely used in the causal inference literature can be applied to predict how 
well an intervention might work when implemented in a new setting where it was not formally 
tested. That is, transportability provides tools to (1) formally evaluate whether findings in one 
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setting could be used to generate valid estimates in another, and (2) if so, estimate what the 
effect would have been had the study been conducted in the new setting. 
Much in the same way that observational causal inference uses directed acyclic graphs 
(DAGs)9 to identify the variables needed to control for confounding, transportability employs 
similar causal graphs—called selection diagrams-- to assist in isolating the important 
characteristics that determine whether and how the effectiveness of an intervention might differ 
between the study population and the population to which we wish to apply the results (the 
target population). Selection diagrams encode formal assumptions about the underlying causal 
relationships and mechanisms through which an intervention is believed to operate in the study 
population as well as assumptions about how the target and study populations differ from one 
another.  
Selection diagram begin with a traditional DAG representing the study population—
paying special attention to the mechanisms through which the intervention is hypothesized to 
affect the outcome and to any characteristics that may affect the outcome or modify the 
effectiveness of the intervention (Figure 1.1).  Selection diagrams explicitly consider how a 
target population differs from the study population by including selection nodes indicating these 
potential differences (Figure 1.2). Unlike standard random variables that are usually included in 
DAGs, selection nodes do not have probability distributions and cannot be influenced by other 
variables in the graph. Instead, they function as indicators that point to where the data 
generating processes may differ between the two settings. In other words, they indicate where, 
if we were to draw a separate DAG for the target population, we might expect the processes 
that give rise to the data might differ between contexts. Importantly, the absence of a selection 
node on a variable indicates that we assume there are no differences in that variable’s 
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distribution between the two populations given its parents (ie. the most proximal causes of the 
variable explicitly represented on the DAG). 
  
Figure 1.1 Directed Acyclic Graph 
 
 
Figure 1.2 Selection Diagram 
 
Selection diagrams reveal first whether the effect of the intervention which was 
estimated in the study population can be transported to a specific alternative target population 
given the data available from both the study population and the target population:  if we can 
measure (and thereby adjust) for enough variables such that all the selection nodes are 
rendered independent of the outcome, the observed estimate could be used to produce a valid 
estimate in the target population, and we would deem that the observed estimate is 
Intervention Mediator Outcome
Baseline Characteristic
Intervention Mediator Outcome
Baseline Characteristic
S
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transportable to the target population.1 Further, we can derive the specific transport formula to 
predict the effect in the target population based on the selection diagram. 
HIV PRE-EXPOSURE PROPHYLAXIS 
 In 2010, the iPrEx study published the first results from a randomized controlled study 
showing a 44% reduction of HIV incidence in those randomized to receive daily oral Truvada for 
pre-exposure prophylaxis (PrEP) compared to placebo.2 In 2012, with the support of additional 
randomized controlled trials (RCTs) in serodiscordant couples3 and heterosexual men and 
women,4 the US Food and Drug Administration approved the use of Truvada for prevention of 
HIV infection.5 In 2015, PrEP was included as a key component of President Obama’s National 
HIV/AIDS Strategy,6 and recently the WHO released updated guidelines for widespread PrEP 
use globally.7 Given the tremendous promise of PrEP thus far and the demonstrated 
effectiveness of widespread HIV testing and treatment,8,9 researchers, advocates, and policy-
makers are beginning to recognize that we now have the necessary tools to dramatically reduce 
– if not completely halt—HIV transmission.10–12 However, despite calls from the CDC, WHO, and 
International AIDS Society for global PrEP roll-out, the United States, France, and South Africa 
remain the only countries to have approved Truvada for prevention of HIV thus far. In order for 
PrEP to reach its full potential, it must be efficiently and widely implemented around the globe. 
The urgent need to address the challenges in PrEP implementation is reflected in the recent 
strategic plans and research priorities of PEPFAR, the National Institute of Mental Health, and 
the Office of AIDS Research 13–17. 
PrEP effectiveness is strongly tied to adherence, 2–4,18–22 and those who are unable to 
achieve sufficient adherence will not benefit from PrEP. Thus, adherence support through 
counseling and monitoring will play an important role in PrEP programs. However, these tools 
are often costly and may require substantial investments in health-systems infrastructure. Thus, 
particularly in resource-limited settings, policy makers will need to efficiently target adherence 
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support tools towards those who need them most. Unfortunately, identifying priority populations 
for adherence support based on clinical studies can be challenging. For example, transgender 
women (TGW) had much lower adherence compared to men who have sex with men (MSM) in 
the iPrEx study, and therefore did not benefit from PrEP randomization according to an 
intention-to-treat analysis.2,23 However, because the TGW and MSM populations in the iPrEx 
study differed significantly in a number of important demographics (including age, education, 
and race), it is possible that the observed differences in adherence between MSM and TGW 
can be fully explained by the other demographic disparities between the populations. Because 
of the large number of differences between MSM and TGW, standard regression approaches to 
attempt to answer this question are not practical.24 
Since 2007, UNAIDS has promoted the “Know your epidemic. Know your response.” 
campaign.25,26 This strategy highlights the need for tailored HIV prevention policies to match the 
heterogeneous nature of the HIV epidemic; no single prevention strategy will work in all 
contexts. PrEP implementation is no different, and policy makers will need to know how PrEP 
fits in to the response to their own HIV epidemic.  Successful PrEP implementation will require 
interpreting and synthesizing the clinical trial data to (1) estimate how well PrEP will work in 
each context, and (2) identify populations who would most benefit from additional adherence 
support.  
 
OBJECTIVES OF DISSERTATION 
 The overall goal of this dissertation is to apply transportability methods to address 
several of these important issues surrounding implementation of HIV pre-exposure prophylaxis. 
This will be addressed over three different chapters: 1) Using transportability to determine 
whether population compositional differences between cisgender men and transgender women 
in the iPrEx study were sufficient to explain the observed effect heterogeneity in the trial; 2) 
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applying transportability to subgroup analyses of the iPrEx study to produce target-specific 
implementation guidance of PrEP; and 3) conducting a simulation experiment to guide variable 
selection strategies for applied transport estimators. 
 Chapter 1 is an application of transportability that addresses a key question about PrEP 
effectiveness in transgender women. Chapter 2 applies transportability to the subgroup 
analyses of the iPrEx study, but also illustrates how this approach can be useful more broadly in 
other subgroup analyses of clinical trials. Chapter 3 is a methods paper that aims to inform how 
transportability theory can best be applied in practice. 
 Individually, each chapter evaluates an important question about PrEP implementation 
or application of transportability theory to real-world questions. Together, these projects 
highlight the broad utility of transportability theory and provide a guide for maximizing the public 
health relevance of randomized trial results. 
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CHAPTER 1: Baseline characteristics explain differences in effectiveness of 
randomization to daily oral TDF/FTC PrEP between transgender women and 
cisgender men who have sex with men in the iPrEx trial 
Megha L. Mehrotra, Daniel Westreich, Vanessa M. McMahan, M. Maria Glymour, Elvin Geng, 
Robert M. Grant, David V. Glidden 
 
 
 
ABSTRACT 
Background: The iPrEx trial found that randomization to daily oral tenofovir disproxil 
fumarate/emtracitabine pre-exposure prophylaxis (PrEP) reduced HIV incidence by half in 
cisgender men who have sex with men (MSM) but found no benefit for transgender women who 
have sex with men (TGW). This unexplained difference is a barrier to PrEP implementation in 
TGW. We assess whether measured baseline participant characteristics can account for the 
difference in effectiveness of randomization to PrEP between TGW and MSM. 
Methods: With data for 2,160 MSM and 339 TGW iPrEx participants who were HIV negative at 
baseline, we used the transportability framework to estimate what the intention to treat (ITT) 
effect of randomization would have been in MSM participants, had they shared the same 
distribution of baseline characteristics as TGW participants. We used a generalization of the 
parametric g-formula to transport the ITT incidence rate ratio (IRR) from MSM to TGW. 
Results: The observed IRR in TGW was 1.29 (95%CI [0.24, 2.35]) and 0.53 (95%CI [0.36, 
0.77]) in MSM. The final transport estimator included condomless receptive anal intercourse, 
number of partners, history of STIs, history of transactional sex, living situation, and baseline 
depressive symptoms. The transported estimate for MSM, i.e., the effect anticipated if MSM had 
the same distribution of these 6 characteristics as TGW, was IRR=1.28 (95%CI [0.12, 40.04]). 
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Conclusions: Population composition differences between MSM and TGW in iPrEx fully 
explained the observed effect heterogeneity in the trial. 
 
INTRODUCTION 
Daily oral tenofovir disproxil fumarate/emtracitabine (TDF/FTC) for HIV pre-exposure 
prophylaxis (PrEP) nearly eliminates the risk of HIV infection in certain populations when taken 
consistently.27–29 However, PrEP will not live up to its full potential unless those at greatest risk 
of HIV infection use it. In particular, PrEP has the potential to be particularly impactful for 
transgender women-- a key population carrying one of the highest HIV burdens globally.30 
However, uptake of PrEP in this population has been low, and this may be in part due to a lack 
of high quality evidence about PrEP in transgender women.31  
iPrEx was the only placebo-controlled randomized study of daily oral PrEP that included 
any transgender women who have sex with men (TGW), and consequently, the trial’s results 
play an outsized role in our understanding of PrEP’s efficacy in this key population.2 Though 
randomization to the active arm was associated with a 44% reduction in HIV incidence in the 
sample overall, stratified analyses found no benefit for TGW (hazard ratio 1.1, 95%CI [0.5, 
2.7]).23 A closer look at measured drug levels in iPrEx found that tenofovir concentrations were 
generally lower in TGW compared to cisgender men who have sex with men (MSM), and drug 
was not detected at the seroconversion visit in any TGW on the active arm who became HIV 
positive.23  
There are at least two possible explanations for the iPrEx results. First, there were a 
multitude of measured baseline differences between TGW and MSM. If these population 
composition differences occurred across characteristics that were important effect modifiers of 
PrEP’s effectiveness—either by affecting adherence to PrEP or by modifying HIV risk—then 
even in the absence of any biological differences in TDF/FTC’s efficacy, the intention-to-treat 
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(ITT) estimate of PrEP’s effectiveness in iPrEx might differ between the two groups.32  Second, 
there may be other unknown or unmeasured differences between TGW and MSM that might 
impact TDF/FTC’s effectiveness. For example, recent small pharmacological studies suggest 
that feminizing hormones might interfere with the ability of tenofovir to block HIV infection by 
lowering the available blood concentration of tenofovir diphosphate.33,34 However, whether these 
potential drug interactions would be sufficient to affect the overall efficacy of TDF/FTC in TGW 
is unclear. Understanding why randomization to PrEP was not effective in TGW in iPrEx may 
have useful implications for PrEP implementation. 
In this manuscript, we aim to better understand to what extent population composition 
differences between MSM and TGW could explain the observed effect heterogeneity in iPrEx. 
We frame this issue as a transportability1 question, and estimate what the ITT effect of 
randomization to PrEP would have been in MSM had they shared the same population 
composition as TGW in the study.24,35 If this transported estimate is similar to the observed ITT 
estimate in TGW, then we can conclude that the effect heterogeneity in iPrEx might be due to 
measured population composition differences alone. If, on the other hand, the transported 
estimate is not similar to what was observed in iPrEx, then this suggests that unique contextual 
or biological factors (or unmeasured differences in population composition) were the sources of 
the effect heterogeneity in the study. 
METHODS 
Study population and procedures 
iPrEx was a placebo-controlled randomized trial of daily oral TDF/FTC PrEP conducted 
between 2007 and 2011 in Brazil, Peru, Ecuador, the United States, South Africa, and Thailand. 
iPrEx enrolled 2499 cisgender men and transgender women who have sex with men.2 All 
participants were HIV-negative at enrollment, reported risk behavior for HIV, and were assigned 
male sex at birth. Gender identity was recorded via a computer assisted structured interview 
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(CASI) where participants were asked how they identified, and any participant who selected 
“trans”, “woman”, or “travesti” (in Brazil, Peru, or Ecuador) was considered to be a TGW for the 
purposes of this analysis. In addition, we included any participant who reported taking 
feminizing hormones (irrespective of gender identity) as a TGW. This is consistent with prior 
subgroup analyses of the iPrEx trial.23  
The same baseline CASI questionnaire also asked participants questions about 
demographics, living situation, relationship status, recent and lifetime sexual history, and 
substance use. Depressive symptoms were measured via an interviewer-administered Center 
for Epidemiologic Studies Depression Scale (CES-D). Detailed study procedures can be found 
in Grant et al, 2010.2 
 
Variable selection and statistical methods 
We first estimated the observed intention to treat incidence rate ratio in MSM (!""#$#) 
and TGW (!""%&') using a Poisson regression that included an offset for follow-up time. We 
excluded individuals who were HIV positive at enrollment or who did not return after their 
enrollment visit. 
We estimated what the incidence rate ratio would have been in MSM had they shared 
the same baseline characteristics as the TGW study participants (!""( #$#). We identified 15 
candidate baseline characteristics that we hypothesized were both associated with HIV 
incidence and differed in distribution between MSM and TGW in iPrEx: age; total number of 
partners in the prior 3 months; any condomless receptive anal sex in the prior 3 months; sexual 
role (top, bottom, or versatile); race; ethnicity (Hispanic/Latino or non-Hispanic/Latino); country 
of residence; highest level of education; marital status; living situation (“With whom do you live 
primarily?”); past month alcohol consumption; history of transactional sex in the past 6 months; 
any history of a sexually transmitted infection in the past 6 months; past month cocaine use; and 
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past week depressive symptoms. We used a data-driven variable selection algorithm to narrow 
this list of 15 potential covariates down to include only those that are necessary and sufficient to 
transport the ITT incidence rate ratio from MSM to TGW. In order for a variable to be selected, it 
must both modify the ITT incidence rate ratio among MSM and differ in distribution between 
MSM and TGW.36  
Using this reduced set of variables ()∗), we applied a generalization of the g-formula37 
to estimate !""( #$#.37,38 This approach is analogous to model-based direct standardization in 
which the MSM population is standardized to resemble the distribution of covariates observed in 
TGW.39 Assuming correct model specification, !""( #$# estimates the ITT incidence rate ratio 
MSM would have had if they had the same distribution of baseline covariates as TGW in iPrEx. 
We also estimate the percent of the observed effect heterogeneity between MSM and TGW that 
can be accounted for by measured population composition differences as +,-.	(122343)6,-.	(122( 343),-.	(122343)6,-.(122789) ∗ 100<. All analyses were performed using R v3.4.1 and STATA 
15.1.40,41 	
RESULTS 
Of the 2499 participants enrolled in iPrEx, 10 were HIV positive at enrollment and 44 did 
not return for follow-up visits. Of the remaining 2445 participants, 290 identified as trans, 29 
identified as women, and 14 identified as men but reported using feminizing hormones. 
Together, these participants comprised the TGW group for this analysis (N=333/2445 (14%)). 
67 (20%) of the 333 TGW participants reported using feminizing hormones.23 
Table 2.1 compares the 15 candidate baseline characteristics between MSM and TGW. 
All but 3 of these variables differed significantly between MSM and TGW (mean baseline CESD 
score, ethnicity, and cocaine use in the past month). In addition, treatment assignment was 
balanced in both groups.  
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The variable selection algorithm identified 6 of these 15 baseline characteristics as being 
necessary and sufficient for transporting the incidence rate ratio: CES-D score; number of 
partners in the prior 3 months; any condomless receptive anal intercourse in the prior 3 months; 
living situation; any history of transactional sex in the prior 6 months; and any STI diagnoses in 
the prior 6 months.  
 In MSM in iPrEx, there were 77 incident HIV infections in the placebo arm and 41 
infections in the active arm; in TGW, there were 10 infections in the placebo arm and 13 in the 
active arm. The ITT incidence rate ratio in MSM (!""#$#) was 0.53 (95%CI [0.36, 0.77]), and in 
TGW the !""%&' was 1.29 (95%CI [0.24, 2.35]). After standardizing the MSM population 
according to the 6 selected baseline characteristics, the transported incidence rate ratio 
(!""( #$#) was 1.28 (95%CI [0.12, 40.04]) (Table 2.2). This corresponds to nearly complete 
(99%) reduction in the observed effect heterogeneity. Overall, after accounting for baseline 
characteristics, the transported ITT incidence rate ratio closely resembles what was observed in 
transgender women in iPrEx. 	
DISCUSSION  
 Differences in population composition between MSM and TGW in iPrEx explained the 
observed effect heterogeneity in the trial results. This finding should allay concerns that 
biological differences in TDF/FTC’s efficacy in TGW or other unmeasured factors were major 
drivers of the effect heterogeneity in iPrEx. 
Whether using feminizing hormones reduces the absorption of tenofovir diphosphate 
enough to produce clinical differences in PrEP’s efficacy remains an important question. Only 
20% of TGW in iPrEx reported taking feminizing hormones, and there were no HIV infections 
among any of the participants taking feminizing hormones who were assigned to the placebo 
arm. Thus, we were unable to rule out the possibility that hormones reduce PrEP effectiveness 
using the iPrEx study data. Nonetheless, our results suggest that differences in a handful of 
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other measured characteristics between MSM and TGW in iPrEx could fully account for the 
effect heterogeneity observed in the trial. 
The small number of transgender women included in iPrEx is a major obstacle for 
understanding PrEP in this key population. By using a transportability approach, we were able 
to better describe the effect heterogeneity in iPrEx after accounting for numerous differences 
between transgender women and cisgender men. Given the limited sample size, this would 
have been impossible using traditional regression adjustment. Additionally, we could have also 
estimated what the ITT result would have been had TGW in the trial had the same baseline 
characteristics as MSM to confirm our findings. Doing so would require fitting a conditional 
model adjusting for baseline characteristics in TGW alone, which was impossible given the 
small sample of TGW. Our findings are valuable despite wide confidence intervals, given that 
iPrEx is the only placebo-controlled randomized trial of PrEP that included any transgender 
women. Any insights about the effects of PrEP in this population are valuable even if substantial 
uncertainty remains.  
The six baseline variables identified as necessary for transporting the incidence rate 
ratio between MSM and TGW were: number of partners in the prior 3 months; any condomless 
receptive anal intercourse in the prior 3 months; history of transactional sex in the prior 6 
months; any STI diagnoses in the prior 6 months; current living situation; and CES-D score. 
Upstream structural and social factors that disproportionately affect TGW likely contribute to 
differences across these variables, so it is possible that these differences will persist in real-
world contexts.30,42–46 Consequently, our results do not imply that effectiveness of TDF/FTC 
PrEP implementation in the general population will necessarily be the same for both 
transgender women and MSM.  Generalization to external settings requires knowledge about 
the population compositions of TGW and MSM in the specific target population of 
interest.1,32,47,48 
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Moving forward, there remains an urgent need for high-quality trans-specific research on 
HIV prevention strategies.49 The effect heterogeneity in iPrEx exemplifies why transgender 
women should not be aggregated with cisgender men when conducting research, and future 
studies should ensure that enough transgender women are included in studies to provide 
adequate power to analyze these groups separately.50 Additionally, further research is needed 
on PrEP for transgender men or non-binary individuals to ensure that PrEP implementation 
programs meet the needs of everyone who could benefit from PrEP. 
Overall, our study--along with others from iPrEx and iPrEx OLE-- suggests TDF/FTC 
PrEP works similarly for MSM and transgender women when accounting for other 
characteristics. PrEP should be offered to anyone at risk of HIV infection regardless of gender 
identity.23
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Table 2.1 Baseline characteristics by gender 
 
  
TGW (N=333) MSM (N=2112) p-value
26 (7) 27 (9) 0.030
17 (8) 17 (8) 0.63
15 (5, 55) 5 (3, 13) <0.001
US 6 (2%) 217 (10%)
Peru 184 (55%) 1192 (56%)
Ecuador 60 (18%) 228 (11%)
Brazil 37 (11%) 327 (15%)
South Africa 4 (1%) 77 (4%)
Thailand 42 (13%) 71 (3%)
Placebo 165 (50%) 1056 (50%)
Active Arm 168 (50%) 1056 (50%)
Non Hispanic/Latino 84 (25%) 597 (28%)
Hispanic/Latino 249 (75%) 1515 (72%)
Black/African American 19 (6%) 186 (9%)
White 38 (11%) 386 (18%)
Mixed/Other 234 (70%) 1452 (69%)
Asian 42 (13%) 88 (4%)
Single 237 (71%) 1594 (75%)
w/Partner 95 (29%) 455 (22%)
Married 0 (0%) 33 (2%)
Divorced 1 (<1%) 28 (1%)
Widowed 0 (0%) 2 (<1%)
With family/friends 226 (68%) 1628 (77%)
w/ Male partner 26 (8%) 120 (6%)
Alone 75 (23%) 299 (14%)
w/ Female partner 1 (<1%) 30 (1%)
other 5 (2%) 35 (2%)
Less than Secondary 125 (38%) 385 (18%)
Completed Secondary 122 (37%) 744 (35%)
Post-Secondary 84 (25%) 960 (45%)
No Answer/Missing 2 (1%) 23 (1%)
Top 14 (4%) 609 (29%)
Bottom 238 (71%) 587 (28%)
Versatile 75 (23%) 858 (41%)
Don't know 6 (2%) 58 (3%)
214 (64%) 790 (37%) <0.001
126 (38%) 515 (24%) <0.001
None/< once a month 63 (19%) 427 (20%)
1-4 per day 67 (20%) 557 (26%)
>=5 per day 150 (45%) 756 (36%)
Refused/Missing/Don't know 53 (16%) 372 (18%)
25 (8%) 105 (5%) 0.055
Ethnicity
Race
0.25
<0.001
0.005Marital Status
Living Situation <0.001
Education Level <0.001
Country
<0.001
<0.001
Treatment assignment 0.88
Any cocaine use in the past month
Alcoholic drinks per day 
in the past month 0.008
Sexual Role <0.001
Any transactional sex in prior 6 months
Any STI diagnosis in prior 6 months
Table 1. Baseline characteristics by gender
CESD Score, mean (SD)
Number of partners in prior 3 months, median (IQR)
Any condomless receptive anal intercourse in the prior 3 
months 286 (86%)
^ 1172 (55%)
Age at baseline, mean (SD)
^   All variables are N (%) except where noted
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CHAPTER 2: Target-specific subgroup analyses for implementation of new 
interventions 
Megha L. Mehrotra, Daniel Westreich, M. Maria Glymour, Elvin Geng, David V. Glidden 
 
ABSTRACT 
Subgroup analyses of randomized controlled trials guide resource allocation and 
implementation of new interventions by identifying groups of individuals who are likely to benefit 
most from the intervention. Unfortunately, trial populations are rarely representative of the target 
populations of public health or clinical interest; unless the relevant differences between trial and 
target populations are accounted for, subgroup results from trials might not reflect which groups 
in the target population will benefit most from the intervention. Transportability provides a 
rigorous framework for applying results derived in potentially highly selected study populations 
to external target populations. The method requires that researchers measure and adjust for all 
variables that (1) modify the effect of interest and (2) differ between the target and trial 
populations. To date, applications of transportability have focused on the external validity of 
overall study results and understanding within-trial heterogeneity; but this approach has not yet 
been used for subgroup analyses of trials. Through an example from the iPrEx study of HIV pre-
exposure prophylaxis, we illustrate how transporting subgroup analyses can produce target-
specific subgroup effect estimates and numbers needed to treat. This approach may lead to 
more tailored and accurate guidance for resource allocation and cost-effectiveness analyses. 
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INTRODUCTION 
Researchers regularly use subgroup analyses of randomized controlled trials (RCTs) to 
find groups within the overall trial population that benefitted most from randomization to the 
intervention.51,52 Policy-makers then prioritize those groups with the lowest numbers needed to 
treat (NNTs)53,54—that is, the number of individuals needed to be offered the intervention to 
prevent one incident outcome-- to receive the intervention. For example, iPrEx2 was a placebo 
controlled RCT that evaluated the safety and effectiveness of combination daily oral tenofovir 
disproxil fumarate/emtracitabine for HIV chemoprophylaxis (PrEP) in transgender women 
(TGW) and cisgender men who have sex with men (MSM). The study found that randomization 
to the active arm was associated with a 44% reduction in HIV incidence compared to the 
placebo arm.2 A subsequent post-hoc subgroup analysis of the trial found that the lowest NNTs 
were among those participants who reported condomless receptive anal intercourse (ncRAI), 
cocaine use, or a sexually transmitted infection.55 These results have subsequently informed 
policy recommendations and cost-effectiveness analyses of PrEP implementation.56–58 
 Using results from subgroup analyses to prioritize implementation relies on the often-
unspoken assumption that the strata-specific effect sizes estimated in the trial accurately reflect 
expected effect sizes in real-world target populations. However, this assumption is unlikely to be 
met in most applications; with the exception of large, pragmatic, cluster-randomized trials, trial 
populations are highly selected and rarely representative of real-world target populations that 
ultimately implement new interventions. Just as differences between trial and target populations 
undermine the external validity of the overall study findings,32 these differences also mean that 
the effect sizes estimated for a subgroup of the trial with a particular characteristic may be poor 
indicators of the expected effect sizes in target populations similar on that characteristic.59–64 
Indeed, even if the overall trial population resembles, on average, a particular target population, 
within subgroups, differences may still exist between the trial and the target populations. 
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 Consider a simple example of a clinic deciding whether to adopt a new blood pressure 
therapy based on evidence from an RCT that enrolled individuals at high cardiovascular risk. 
The hypothetical RCT found that men benefitted more from the new therapy than women; cost-
effectiveness analyses based on these results suggested that the clinic should only offer men 
the new therapy but keep women on the previous standard of care. Because individuals at high 
cardiovascular risk were differentially recruited for the study, the proportion of women in the trial 
who smoked was much higher than in the clinic population. If the new therapy is not effective 
among tobacco users, this could account for the lackluster results among women in the trial. If 
the trial had been conducted in the clinic population, where smoking is less common among 
women, the new therapy would have been deemed cost-effective for men and women alike. In 
this simple example, using the subgroup analyses from the RCT without accounting for 
differences in the trial and target populations would lead to incorrect decisions about who to 
prioritize to receive the new therapy.  
Recent developments in causal inference provide a principled approach for extending—
or transporting-- the results of a study to an external target population.65 This approach sets 
forth the principles and conditions that enable using the results of a study to infer what those 
results would have been had the study been conducted in an external target population.1,32,66 To 
do so, all variables that (1) modify the effect of the intervention and (2)  differ in distribution 
between the study and target populations must be measured and accounted for.1,65,67 When 
differences between populations are limited to pre-treatment (baseline) covariates, 
transportability conceptually coincides with standardization across several characteristics.68   
To date, transportability has previously been applied to transport average treatment 
effects to new target populations47,69,70 or to understand observed heterogeneity between sites35 
or groups71 in a trial. The theory also presents a promising solution for producing target-specific 
guidance for how to prioritize new interventions, but to our knowledge this framework has not 
yet been employed for these purposes. Here, we use an example from the iPrEx study of HIV 
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chemoprophylaxis2 to illustrate how to apply transportability theory and estimators to transport 
subgroup effect estimates and NNTs to two specific external target populations. We discuss the 
necessary assumptions and data that are required for this approach to be successful in practice. 
METHODS 
Motivating example 
The iPrEx study population comprised a heterogeneous group of 2499 MSM and TGW 
in Brazil, Peru, Ecuador, the United States, South Africa, and Thailand. All participants were 
HIV-negative at enrollment, reported risk behavior for HIV, and were assigned male sex ant 
birth. The median age at enrollment was 25 and most participants had not received a college 
education.2 In aggregate, the iPrEx study population is unlikely to be representative of other 
target populations planning to roll out PrEP. Moreover, the populations who are at highest risk of 
HIV vary across the world, and guidance for how to prioritize PrEP should be tailored 
accordingly to each specific setting.26 
Suppose we are interested in implementing PrEP in two clinics that serve young Latino 
TGW and MSM with men in San Francisco and Chicago. The clinics have limited resources, 
and each would like to target outreach and marketing of PrEP to those who are most likely to 
benefit from it. Here, we focus on subgroups that can easily be measured via survey or self-
report: gender identity, including cisgender men or transgender women (=>=	and	?@A); recent 
sexual behavior, including any condomless receptive anal intercourse in the prior 3 months 
(BC"D!) and primary sexual role (EFG, IFEEFJ, KLMNOEPQL); and any cocaine use in the prior 6 
months. To generate customized recommendations for each clinic based on these subgroups, 
we estimate what the subgroup-specific intention-to-treat (ITT) one-year HIV risk differences 
and NNTs would have been had the iPrEx trial been conducted in each clinic population.  
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Data and measurements  
 The iPrEx study randomized 2499 HIV-negative MSM and TGW to receive either daily 
oral PrEP or placebo, and participants were followed from 2007-2010. We included all 
participants from the iPrEx trial who were HIV-negative at their enrollment visit and who had 
contributed any follow-up time (N=2441).  
To represent our two target populations, we used all HIV-negative participants in the San 
Francisco (N=210) and Chicago  (N=263) study sites of the Latino MSM Community 
Involvement Study.72,73 The study was a cross-sectional survey conducted in 2004 of Latino gay 
or bisexual cisgender men or transgender women that aimed to collect information about the 
participants’ experiences in their community, sexual behavior, and substance use. Data from the 
Latino MSM Community Involvement study were accessed through the Inter-university 
Consortium for Political and Social Research.73  
In both the iPrEx and the Latino MSM Community Involvement studies, participants were 
asked about their sexual behavior, demographics, STI history, and alcohol and drug use via a 
computer assisted structured interview (CASI).2,72,73  
Notation, target parameters and identification 
Our goal was to estimate the subgroup-specific ITT HIV risk difference at one year 
between those randomized to the PrEP arm and those randomized to the placebo arm and the 
corresponding numbers needed to treat to prevent one infection per year in iPrEx, San 
Francisco, and Chicago. Our subgroups variables of interest were cisgender men who have sex 
with men (=>=); transgender women who have sex with men (?@A); people who reported any 
condomless receptive anal intercourse in the prior 3 months (BC"D!); primary sexual role 
(EFG, IFEEFJ, KLMNOEPQL); and people who reported using cocaine in the prior 6 months (CFCOPBL). 
We use random variable R to denote treatment assignment where R = 1 indicates assignment to 
receive PrEP and R = 0 indicates assignment to the placebo arm. We use T!UV to represent the 
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counterfactual outcome that would have been observed if R = W were assigned. > indicates the 
population of interest where > = 0 is the iPrEx study population; > = N′ is one of the two target 
populations where NY ∈ {\ℎPCO^F, >OB	_MOBCPNCF}. @ = ^ indicates the subgroup of interest 
where ^ ∈ {=>=, ?@A, BC"D!, EFG, IFEEFJ, KLMNOEPQL, CFCOPBL}. 
 
We define the ITT effect in subgroup @ = ^ in population > = N as: abc = defghijk − fghijmno = b, p = c	)     (Eq.  1) 
and the NNT54 for each subgroup @ = ^ in population > = N as: 
 qbc = knabc n = knd(fghirk6fghirmnojb,pjc)n    (Eq.  2) 
 For simplicity, we assume there was no measurement error. To identify the target 
parameters within the iPrEx study population, we must assume: 
1. Conditional treatment exchangeability: R is independent of (T!Us, T!Ut) given @ = ^, and > = 0. That is, there is no confounding of the association between treatment assignment and 
HIV incidence in the iPrEx study population within subgroup @ = ^. This assumption is met 
by randomization of treatment assignment in the iPrEx trial. 
2. Treatment positivity: u(R = W	|@ = ^) > 0 for all ^ for which u(@ = ^) > 0. That is, there 
must be a non-zero probability of being assigned each treatment for each subgroup.74 
Randomized treatment assignment in the iPrEx trial guarantees that there are no structural 
positivity violations, but does not guarantee the absence of practical positivity violations, 
which are more likely to occur in smaller samples in subgroups.   
In addition to the above assumptions, to identify the transported target parameters we must also 
meet the following criteria24: 
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3. Conditional population exchangeability: x(T!U|> = 0,)b, R, @ = ^) = 	x(T!U|> =N′,)b, R, @ = ^). Within subgroup @ = ^, the iPrEx study population and target population 
are exchangeable with respect to HIV incidence conditional on some set of measured 
characteristics ()b) and treatment assignment. 
4. Population positivity:	ue> = 0, R = Wn)b, @ = ^y > 0	u)b|zj&,{j$Y	O. L. That is, every 
combination of	)b = }b that could be drawn from the distribution of )b	in each strata @ =^ within each target population is represented in the iPrEx study population in @ = ^	and 
has a non-zero probability of being assigned R = W.  
Thus, for each subgroup @ = ^ we must condition on the set of variables )bthat ensures that 
assumption 3 is met.  
Selection diagrams are augmented directed acyclic graphs75,76 introduced by Pearl and 
Bareinboim that assist in identifying a set of variables that satisfies assumption 3 above. In 
these graphs, selection nodes are not standard random variables. Instead, they indicate where 
differences in the causal model might exist between the trial and target populations.1,77 An effect 
can be transported across the populations if there exists a set of variables that, if conditioned 
on, will make all the selection nodes independent (or d-separated78) from the outcome 
variable.1This set of variables, called the s-admissible set, satisfies the conditional population 
exchangeability assumption given above. For rules on how to evaluate d-separation in selection 
diagrams, please see Appendix A. 
Figure 3.1 depicts our proposed selection diagram representing the assumed causal 
model within the iPrEx study and assumed differences between the study population and each 
target population. Based on our selection diagram, we identified the s-admissible set  of 
variables ()b) for each subgroup analysis, i.e.  the set of variables that is sufficient to d-
separate all the selection nodes from the outcome conditional on the subgroup of interest such 
that T!U ⊥ >	|	R, @ = ^,)b: 
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Gender identity (p and Äo)): age, education, number of partners, BC"D!, cocaine use, and alcohol consumption. 
Condomless receptive anal intercourse (ÅÇÉÑg): age, education, number 
of partners, cocaine use, alcohol consumption. 
Primary sexual role (ÖÜá, àÜÖÖÜâ, äãåcçÖéèã): age, education, number of 
partners, BC"D!, cocaine use, alcohol consumption, and gender 
identity. 
Cocaine use: age, education, number of partners, BC"D!, and alcohol 
consumption 
 
 Given the above assumptions, the target parameters within the iPrEx study population 
are identified by:  abm ≡ defghijk − fghijmno = b, p = m)       
= d[fgh|i = k, o = b, p = m] − d[fgh|i = m, o = b, p = m]           (Eq.  3) 
and: qbm = knabmn = k|d[fgh|ijk,ojb,pjm]6d[fgh|ijm,ojb,pjm]|   (Eq.  4) 
 
The transported target parameters are the subgroup-specific ITT effects and NNTs had the 
study been conducted in each target population (San Francisco or Chicago) and are identified 
by: 
 ì&$Y ≡ x(T!UVjt − T!UVjs|@ = ^, > = N′	) 
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= ded[fgh|i = k,)b, o = b, p = m]|p = cYy     
 −ded[fgh|i = m,)b, o = b, p = m]|p = cYy  (Eq.  5) 
And the transported NNTs are:   î&$ï = tñó84ïñ  = kded[fgh|ijk,)b,ojb,pjm]|pjcYy6ded[fgh|ijm,)b,ojb,pjm]|pjcYy  (Eq.  6) 
Estimation 
 To estimate the ITT risk difference for each subgroup in iPrEx, we used the parametric g-
formula. We fit a log-binomial regression model with main terms for treatment assignment and 
the subgroup variable as well as an interaction term between treatment assignment and 
subgroup. Using this model, we predicted the marginal incidence risk difference at one year 
within each subgroup. Because treatment was randomly assigned, we did not adjust for any 
additional covariates in each subgroup analysis in the iPrEx study population.  
 To transport the ITT effects, we first generated stabilized inverse odds of selection 
weights79 using the following formula: 
!ò>Aô = öue>ô = 0|)b, @ôyue>ô = N′n)b, @ôy ∗ 	u(>ô = NY, @ô)u(>ô = 0, @ô) , >ô = 0,0																						, >ô = N′  
Each component of the IOSW was estimated using logistic regression. Note that because the 
iPrEx study population is not a subset of either target population, inverse odds weights were 
used instead of inverse probability weights. In settings where the study population is fully nested 
within the target population, inverse probability weights would be an appropriate analogous 
estimator.68,79 
The inverse odds weights were used to fit weighted log-binomial regressions with an 
interaction between treatment assignment and subgroup. We used this model to predict the 
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number of incident HIV infections at one year by treatment assignment within each subgroup in 
each target population, and we calculated the transported marginal risk difference. Standard 
errors and 95% confidence intervals were calculated using a bias corrected and accelerated 
bootstrap80 with 2000 resamples. The bootstrap resampled both the iPrEx study population and 
target populations, and then calculated new weights and fit the weighted log-binomial regression 
on each bootstrap sample. This ensured that the variability in the target population was also 
incorporated into the standard errors. 
 The number needed to treat was estimated as the inverse of the difference in risk of HIV 
infection at one year of follow-up81 giving the number of individuals who need to be offered PrEP 
needed to avert one infection in one year. 
 All analyses were conducted using R version 3.4.140 and STATA version 15.1.41 
RESULTS 
There were differences in most baseline characteristics across settings (Table 3.1), and 
in particular, the iPrEx study population had on average more recent sexual partners and more 
individuals reporting recent condomless receptive anal intercourse. 
Figure 3.2 shows the subgroup-specific intention-to-treat risk differences at one year, 
and Figure 3.3 shows the numbers needed to treat to prevent one infection in each population. 
In all settings, cocaine users had the lowest number needed to treat. In Chicago, the NNT was 
next lowest among those whose primary sexual role was “bottom,” whereas in iPrEx the sexual 
role with the lowest NNT was “versatile.” In all settings, PrEP is not expected to be beneficial for 
those whose primary sexual position is “top.” Finally, though there were apparent differences in 
the effectiveness of randomization to PrEP between cisgender men and transgender women in 
iPrEx, after transporting the results to San Francisco these gender differences are diminished. 
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DISCUSSION 
 Subgroups with the lowest NNTs in trial populations may not be the same groups that 
would have the lowest NNTs in target populations. Without formally accounting for differences 
between trial and target populations, subgroup-specific effect sizes and NNTs from trials may 
not provide useful guidance for implementing new interventions in target populations. The 
transportability framework is a rigorous solution for generating target-specific subgroup results 
and tailored implementation guidance. 
Assuming that we have adequately measured and accounted for all of the characteristics 
that both modify the effectiveness of randomization to PrEP and differ between the study and 
target populations, our worked example demonstrates how subgroup analyses might give 
meaningfully different guidance regarding resource allocation if they are transported to the 
specific target populations. In iPrEx, those who indicate that their primary sexual role is 
“versatile” have much lower NNTs than other sexual roles. However, after transporting the 
results to Chicago, we see that the sexual role with the lowest NNT is “bottom,” and in San 
Francisco we find that those who report recent condomless receptive anal intercourse have a 
lower NNT than any specific sexual role. Prioritizing PrEP according to self-reported sexual role 
is appealing, as the information can easily be gathered in a clinic-setting through a single 
question. To use sexual role as a means to prioritize PrEP efficiently however, the iPrEx results 
must be transported to each target population with distinct covariate distributions.  
 The application of transportability relies on the availability of high-quality individual-level 
data in both the trial and target populations. The outcome itself does not need to be measured 
in target populations—which is particularly helpful for rare or hard to measure outcomes like HIV 
incidence-- but in order for the transportability assumptions to reasonably be met, there needs 
to be a rich dataset of characteristics that are associated with the outcome gathered in the 
target population. Which characteristics need to be measured depends on the intervention and 
outcome of interest; simply gathering basic demographic information may not always be 
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sufficient for a particular outcome. Similarly, individual-level trial data including all relevant effect 
modifiers need to be available to generate policy-relevant recommendations. These data 
requirements are not trivial, but as increasingly more studies make their data available for 
secondary analyses, and as more data are collected and aggregated on individuals in real-world 
target populations, transportability will likely soon become more feasible in applied research. 
Though the particular examples presented here are helpful for illustrating how 
transportability can be used to improve subgroup analyses, there are several important 
limitations that preclude interpreting these findings substantively. First, the Latino MSM 
Community Involvement Study was conducted in 2004, so the characteristics and behaviors 
described in these data may not reflect the current needs of these populations. Next, as PrEP 
has become more widely adopted around the world, the characteristics of those individuals who 
are likely to adhere to PrEP has undoubtedly changed. This means that, assuming we have met 
all the assumptions necessary for transport and that our models were correctly specified, our 
transported estimates could only be interpreted as the effects we would have observed had the 
iPrEx trial been conducted in each target population at the time it was conducted (2007-2010). 
This limitation is not unique to our example. Unless trial results are transported immediately at 
the end of the study, factors that affect uptake, adherence, and effectiveness of a new 
intervention are likely to change, and the transported results will become less relevant over 
time. 
The results of our illustrative example were uncertain, as demonstrated by the wide 
confidence intervals in Figure 3.2. The numbers needed to treat, which are derived from the risk 
differences, are similarly uncertain--particularly for those subgroups that included few individuals 
(cocaine users, for example). This uncertainty reflects the fact that both the study and target 
populations included relatively small samples, and also underscores an important challenge in 
transporting subgroup analyses more broadly. Trials are often underpowered to detect subgroup 
differences, and transport estimators may reduce the precision of subgroup estimates. While 
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other transport estimators such as the parametric g-computation transport estimator and 
targeted maximum likelihood might be more efficient than the IOSW estimator, researchers 
applying these tools in practice should be careful in weighing the bias-variance tradeoff for their 
particular application. 
Finally, a central issue that researchers will face when employing transportability 
methods is results are likely to be sensitive to the assumptions made in the selection diagram, 
and many of these assumptions are untestable. Selection diagrams, as with any other causal 
graph, are typically built using a combination of prior knowledge, subject matter expertise, and 
previously published literature. Usually there will still be considerable uncertainty about the 
accuracy of these diagrams. In practice, quantitative bias analyses that put reasonable bounds 
on the transported estimates are merited and further work should explore how best to 
implement these analyses for transportability. 
 Transportability is a transparent framework for describing, evaluating, and testing the 
assumptions needed to produce target-specific subgroup effect estimates and NNTs. Moving 
forward, researchers publishing trial results should ensure that all important variables that might 
be relevant for transporting findings to target populations are made available so that local health 
departments, policy-makers, and other researchers can generate tailored recommendations for 
how to implement new interventions. 
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 Table 1. Demographic Characteristics
16.9 (35.6) 8.0 (10.2) 7.3 (10.0)
18-25 1374 (55.0%) 37 (17.6%) 76 (28.9%)
26-35 730 (29.2%) 78 (37.1%) 113 (43.0%)
36-45 270 (10.8%) 66 (31.4%) 50 (19.0%)
>45 125 (5.0%) 29 (13.8%) 24 (9.1%)
Less than HS 524 (21.0%) 57 (27.1%) 63 (24.0%)
HS 884 (35.4%) 38 (18.1%) 68 (25.9%)
College 1091 (43.7%) 115 (54.8%) 132 (50.2%)
Cisgender Man 2174 (87.0%) 172 (81.9%) 249 (94.7%)
Transgender Woman 325 (13.0%) 38 (18.1%) 14 (5.3%)
None/< once a month 496 (19.8%) 90 (42.9%) 68 (25.9%)
1-4/day 635 (25.4%) 72 (34.3%) 85 (32.3%)
>=5/day 931 (37.3%) 47 (22.4%) 108 (41.1%)
Don't Know 437 (17.5%) 1 (0.5%) 2 (0.8%)
No 2368 (94.8%) 187 (89.0%) 214 (81.7%)
Yes 131 (5.2%) 23 (11.0%) 48 (18.3%)
Top 641 (25.7%) 34 (16.2%) 37 (14.1%)
Bottom 834 (33.4%) 89 (42.4%) 132 (50.2%)
Versatile 1024 (41.5%) 87 (41.4%) 94 (35.7%)
No 1014 (40.6%) 159 (75.7%) 185 (70.3%)
Yes 1485 (59.4%) 51 (24.3%) 78 (29.7%)
iPrEx (N=2499) San Francisco (N=210) Chicago (N=263)
ncRAI in prior 3 months^
Age at baseline
Number of male parters in prior 3 
months
Highest level of education
Gender Identity
Alcohol consumption in prior month
Primary sexual position
Cocaine use in prior month
 ^any condomless receptive anal intercourse in the prior 3 months
Table 3.1. Baseline characteristics by population. 
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Figure 3.1 Z is treatment assignment; Adh is adherence; Age is age at baseline; Gender is 
gender identity; Education is highest level of education; Sexual role is primary sexual position 
(“top”, “bottom”, “versatile”); Alcohol is prior month alcohol consumption; Cocaine is prior month 
cocaine use; ncRAI is any condomless receptive anal intercourse in the 3 months prior to 
baseline; Number of partners is total number of male partners in the 3 months prior to baseline. 
  
Z HIV
Education
ncRAI
Sexual role
Gender
Adh
Age
Alcohol
Cocaine
Number of 
partners
S
S
S
S
S
S
S
S
Figure 1. Z is treatment assignment; Adh is adherence; Age is age at baseline; Gender is gender identity; Education is highest level of education; Sexual role is primary sexual position 
(“top”, “bottom”, “versatile”); Alcohol is prior month alcohol consumption; Cocaine is prior month cocaine use; ncRAI is any condomless receptive anal intercourse in the 3 months prior to 
baseline; Number of partners is total number of male partners in the 3 months prior to baseline.
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Figure 3.2.  Subgroup-specific risk differences in iPrEx, San Francisco, and Chicago 
 
 
Figure 2. Subgroup-specific risk diﬀerences in iPrEx, San Francisco, and Chicago. 
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Appendix 
d-separation rules for selection diagrams 
  The d-separation rules as described by Pearl, 198878 that are traditionally applied to 
directed acyclic graphs and other causal diagrams can also be applied to determine if there 
exists a set of variables such that conditional on that set, the conditional population 
exchangeability assumption is fulfilled. 
Consider the selection diagram given in Supplementary Figure 3.1. In this example, A is the 
exposure, Y is the outcome, W1, W2, and W3 are other covariates, and the S nodes are the 
selection nodes. To transport the causal effect of A on Y from the study population to the target 
population, we must be able to identify a set of variables that makes all of the selection nodes 
independent of the outcome—or d-separates all of the selection nodes from the outcome. 
To test whether all the selection nodes in a selection diagram are independent of the 
outcome, we need to test whether all of the paths from the selection nodes to the outcome can 
all be blocked by conditioning on other measured variables. A path between S and Y is blocked 
if: 
1) SàW1àY and W1 is conditioned on  
or 
2) SàW2ßY and W2 is not conditioned on. 
W2 is a collider, and conditioning on a collider opens a path between the parents of the collider.  
This could be corrected by simultaneously conditioning on W3, thus blocking the path.  
 In Supplementary Figure 1, we would need to condition on W1 to block all the paths 
between the selection nodes and Y. If we condition on W2, we would open a path between the 
selection node and Y through W3. 
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Supplementary Figure 3.1. Selection Diagram  
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CHAPTER 3: Variable Selection for Transportability 
Megha L. Mehrotra, M. Maria Glymour, Elvin Geng, Daniel Westreich, David V. Glidden 
 
ABSTRACT 
Transportability provides a principled framework to address the previously intractable 
problem of applying study results to new populations. Several transport estimators have been 
developed to use alongside the formal transportability theory.  Here, we consider the problem of 
selecting variables for these transport estimators. We provide a brief overview of the 
transportability framework and illustrate that though selection diagrams are a vital first step in 
variable selection, these graphs alone may not identify the optimal set of variables for 
generating an unbiased transport estimate. Next, we conduct a simulation experiment assessing 
the impact of including unnecessary variables on the performance of the parametric g-
computation transport estimator. Our results highlight that the types of variables included can 
affect the bias, variance, and mean squared error of the estimates. We find that addition of 
variables that differ between the source and target populations but that don’t cause the outcome 
can increase the variance and mean squared error of the estimates, while inclusion of causes of 
the outcome—regardless of whether they modify the causal contrast of interest—reduces the 
variance of the estimates without increasing the bias. Exclusion of variables that are causes of 
the outcome but are not modifiers of the causal contrast does not increase bias. These findings 
suggest that variable selection approaches for transport should prioritize identifying and 
including all causes of the outcome in the study population rather than focusing on differences 
between the populations. 
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INTRODUCTION 
The transportability framework, which builds on the theoretical foundations of causal 
inference, outlines the necessary rules and assumptions for determining when and how a 
causal effect estimated in one study population can be applied to an external target 
population.65 These tools present a promising solution to the long-standing challenge of 
assessing the external validity of research findings and can also be used to better understand 
observed effect heterogeneity within a study.35,38,82  
 However, applying transportability methods to real-world problems is not always 
straightforward. A central challenge that researchers face in using these tools is deciding what 
variables need to be measured and included in their transport estimators. Similar to variable 
selection for confounding adjustment,83 these decisions can greatly affect the bias and variance 
of the transported effect estimate, but to our knowledge, little has been written about different 
variable selection strategies for transport. 
  Ideally, subject matter expertise and a clear understanding of the study and target 
populations would be the primary guide for variable selection decisions. Selection diagrams—
the causal graphs used for transport-- facilitate using prior knowledge of the underlying causal 
mechanisms to identify a set of variables that would be sufficient to transport an effect from a 
study population to a given target population. However, because of uncertainty about the 
underlying causal structure or mechanisms in real-world applications, using selection diagrams 
alone may be insufficient to narrow down the list of candidate variables to include only those 
that are necessary for a given application. Ultimately, even after careful use of selection 
diagrams, an applied researcher working with a finite sample of data will likely have to decide 
which variables she thinks are essential from an extensive list. 
 Here, we provide a practical guide to variable selection for transportability. We begin by 
briefly reviewing the transport framework and graphical approach to variable selection. Next, we 
introduce the minimally sufficient transport set, and illustrate why transporting causal contrasts 
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may require fewer variables than a standard selection diagram may indicate. Finally, we 
categorize the different types of variables (according to causal structure) that might be included 
in transport estimators and use Monte Carlo simulation experiments to evaluate how inclusion 
or exclusion of different variable types affects bias, variance, and mean squared error of the 
parametric g-computation transport estimator. 
NOTATION AND DEFINITIONS 
o Source population—population you are transporting results from (ie. study population) 
o Target population—population you are transporting results to  
o u(õV)-- the distribution of counterfactual outcome õ if exposure R is assigned value W.  
o Φ -- a causal quantity that is a function of the counterfactual outcome distribution. For 
example, a causal contrast, i.e. a causal risk difference (x(õVjt − õVjs)). 
o S – selection node indicating population membership where N ∈ {0,1} and > = 1 indicates 
the source population and > = 0 indicates the target population. These nodes are not 
standard random variables, but instead indicate where the data generating mechanisms 
may differ between the two populations. 
o ûü† – an s-admissible transport set defined as a set of variables that d-separates all 
selection nodes from the outcome variable (õ ⊥ >	|	Äpc). There may be more than one s-
admissible set for a given graph. 
o ûü – a transport set defined as the set of variables included in a transport estimator. The 
transport set may or may not be an s-admissible set.  
o °üûü – a minimally sufficient transport set. The smallest possible s-admissible transport 
set. There may be more than one MSTS for a given problem. 
 
TRANSPORTABILITY 
The goal of transportability is to extend or apply the results of a study conducted in one 
population (the source population) to another population (the target population). Why the results 
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of a study conducted one population may not apply to another is intuitive: if there are 
characteristics or factors that modify the effectiveness of the intervention under study and the 
distribution of these characteristics differs between the source and target populations, then we 
would expect that the results of a study would similarly vary depending on which population it 
was conducted in. If we are able to measure and account for those characteristics that both a) 
modify the effectiveness of the intervention and b) differ between two populations, we should be 
able to apply study results gathered in the source population to an external target population 
without having to repeat the entire study.  
The transportability framework formalizes this intuition and sets forth formal 
mathematical rules and conditions under which the results of a study can be transported from a 
source population to a target population.65 We define u(õV) as the counterfactual distribution of 
outcome õ if exposure R is assigned value W for all possible values of õ and R. This quantity can 
be thought of as the most general definition of a causal effect, as any causal contrast (ie. the 
causal risk difference x(õVjt − õVjs)) is a function of this counterfactual distribution. u(õV) can 
be transported from a source population (> = 1) to a target population (> = 0) if the following 
assumptions are met: 
1) S-admissibility (or conditional population exchangeability): õ ⊥ >	|	Äpc where Äpc is 
an s-admissible set. 
2) Population positivity: u(> = 1|Äpc = Öcc) > 0	for every Öcc that has a positive density 
in the target population. That is, all values of the s-admissible set  
 
Selection Diagrams for Variable Selection 
To illustrate the transportability framework in action, we use a simple toy example 
loosely motivated by the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment 
and Disability (FINGER)84. Suppose we conducted a randomized controlled trial evaluating 
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whether a multicomponent behavioral intervention was effective in reducing the 2-year risk of 
cognitive decline compared to standard of care among participants in Finland. The study found 
that randomization to a multicomponent behavioral intervention was effective in reducing the 2-
year risk of cognitive decline, but we want to know what the results of this trial would have been 
had it been conducted in a US-based target population.  
Figure 4.1 represents the true data generating mechanism for this toy example. For 
simplicity and without loss of generality, we assume that there are only two additional variables 
that might affect cognitive decline: systolic blood pressure >140 mmHg; and being a carrier of 
the apolipoprotein E-¢4 (APOE-¢4) variant. We define our outcome as risk of a 10% reduction in 
neurocognitive test battery (NTB) score after 2 years of follow-up. We define our source 
population > = 1 as the Finnish study population and our target population > = 0	as the US-
based target population; R is randomized treatment assignment; § = 1 (systolic blood pressure 
> 140mmHg) and @ = 1 (APOE-¢4 carrier) both affect the risk of NTB score reduction by year 2. § and @ differ in distribution between the study and target populations. 
Akin to how directed acyclic graphs (DAGs) are used to select variables to control for 
confounding, selection diagrams are causal graphs used to determine which variables satisfy 
the s-admissibility criteria for transportability. To create a selection diagram, we begin by 
drawing a DAG that represents the data-generating model for the source population. Next, we 
add selection nodes that indicate where there might be differences in the data-generating 
models between the source and target populations (Figure 4.2). Selection nodes are not 
standard random variables; instead, they are indicators that point to the portions of the data-
generating model that might differ between the two populations. 
Any set of variables that d-separates all of the selection nodes from the outcome is an s-
admissible set (Äpc) for transporting u(õV). Note that a given graph may reveal more than one 
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s-admissible set. Based on the selection diagram given in Figure 4.3, the s-admissible set for 
this example is systolic blood pressure >140mmHg and APOE-¢4 (Äpc = {§, @}). 
Throughout this manuscript we restrict our discussion to scenarios in which selection 
nodes are only directed at pre-treatment variables. Transporting results in situations where 
there are selection nodes directed at mediating variables requires additional measurements and 
assumptions that are beyond the scope of this manuscript. For background on transporting 
causal effects when selection nodes are directed at mediating variables, we point readers to 
Appendix 3 of Pearl and Bareinboim, 20111 and Bareinboim and Pearl, 201285 for more details. 
MINIMALLY SUFFICIENT TRANSPORT SET 
A minimally sufficient transport set (=>?>) is the smallest possible s-admissible set that 
would satisfy assumption 1 for transporting a particular causal quantity from a source population 
to a target population. Though selection diagrams are useful for identifying s-admissible sets, in 
practice, they may not be able to isolate the =>?> for two key reasons.  
 
Transportability of causal contrasts 
 The transportability framework gives the assumptions and criteria for transporting the full 
counterfactual distribution of outcomes u(õV) from the source population to the target 
population. However, in many applications, researchers may only be interested in transporting a 
particular causal quantity (e.g. a causal contrast or mean outcome value). If the causal quantity 
of interest (Φ) is a function of u(õV), then any set of variables that is s-admissible for 
transporting u(õV) would also be s-admissible for transporting Φ. However, there may be some 
variables that are necessary to transport u(õV) that would be unnecessary for transporting Φ. 
For example, according to the selection diagram given in Figure 4.2, the s-admissible set to 
transport u(õV) includes both § and @. This is also apparent from the structural equations in 
Figure 4.1: u(õ = 1) depends on both § and @. However, suppose we are only interested in 
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transporting the causal risk difference between those assigned to the intervention arm and 
those assigned to the treatment arm: Φ = 	u(õVjt = 1) − u(õVjs = 1) = u(õ = 1|R = 1) − u(õ = 1|R = 0) 
From the structural equations in Figure 4.1, we see that this quantity only depends on §: u(õ = 1|R = 1) − u(õ = 1|R = 0) = −.4§ − .001(1 − §) 
We can re-draw the selection diagram to reflect that we only want to transport this risk 
difference (Figure 4.3) and to indicate that the risk difference does not depend on @; only § is 
required to d-separate the risk difference from the selection nodes.  
 
The transport formula for transporting u(õV)	from the source to the target population using the 
transport set {§, @} is:	u(õV|> = 0) =••u(õ = 1|R, @, §, > = 1)u(§, @|> = 0)¶&  
And the transport formula for transporting Φ using the transport set {§} is: 
 Φ = 	u(õVjt = 1	|> = 0) − u(õVjs = 1|> = 0)=•u(õ = 1|R = 1, §, > = 1)u(§|> = 0)¶−	•u(õ = 1|R = 0, §, > = 1)u(§|> = 0)	¶  
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Figures 4.1- 4.3 Structural causal model, standard selection diagram, and modified selection 
diagram illustrating that fewer variables might be needed to transport a causal contrast than for 
transporting the full counterfactual outcome distribution. 
 
Table 4.1 shows the results of using each transport set to transport the mean outcome 
in each arm; the risk difference between arms; and the risk ratio between arms. We see that Eq. 
4, which includes both causes of the outcome, allows us to accurately transport all 3 quantities, 
but Eq. 5 is sufficient to transport our causal quantity of interest (the risk difference). 
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  P(Y=1) Risk 
Difference 
Risk Ratio 
Truth 
ß(® = k|i = m, p = m) 0.680 
-0.121 0.823 ß(® = k|i = k, p = m) 0.559 
Transported 
using {©, o} Transported  ß(® = k|i = m, p = m) 0.680 -0.121 0.823 Transported  ß(® = k|i = k, p = m) 0.559 
Transported 
using {©} Transported  ß(® = k|i = m, p = m) 0.632 -0.121 0.809 Transported  ß(® = k|i = k, p = m) 0.511 
 
 This toy example illustrates that transporting a specific causal quantity may require fewer 
variables than would be necessary for transporting the full counterfactual distribution. In 
practice—when the true data-generating model is unknown—knowing which variables from the 
s-admissible set for transporting u(õV) are unnecessary for transporting Φ requires parametric 
assumptions on the outcome-generating function that may be difficult to justify. As a result, 
researchers may reasonably choose to use the s-admissible set for u(õV) to avoid making these 
types of parametric assumptions even if doing so increases the chance that unnecessary 
variables are included in the transport estimators.  
 
Uncertainty in causal diagrams 
 Even if a researcher intends to transport the entire counterfactual outcome distribution, 
uncertainty about the data generating processes in each population will lead to including 
extraneous variables in transport estimators. For selection diagrams to be most effective, they 
need to adequately and honestly reflect our prior knowledge and assumptions about the causal 
Table 4.1 shows the transported risk difference and risk ratio adjusting for APOE-¢4 (G) and 
systolic blood pressure (B) or systolic blood pressure alone. If the target parameter is the 
risk difference, we see that adjusting for systolic blood pressure alone is sufficient. 
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mechanisms underlying the observed (and unobserved) data. As with all causal graphs, 
excluding edges or selection nodes from a selection diagram is a stronger assumption than 
including them.86 That is, the most conservative graph would include edges between all random 
variables and would include selection nodes directed at every random variable. This graph 
would indicate that we think there is a possibility that each variable may cause the others (or be 
associated with through a common ancestor) and there may be differences anywhere in the 
data-generating model between the source and target populations. 
 In most (if not all) applied settings, there is often considerable uncertainty about the true 
data-generating model. Further, we often have little knowledge about how two populations might 
differ from one another. As a result, selection diagrams that honestly capture this uncertainty 
are likely to include more selection nodes or edges than are present in truth. The s-admissible 
sets based on these graphs will therefore likely include many more variables than necessary.  
Overall, selection diagrams are an important tool to guide variable selection, but in most 
applications, selection diagrams may not be able to reveal a minimally sufficient transport set 
and transport estimators based on selection diagrams are likely to include additional 
unnecessary variables. How these extraneous variables might affect the performance of 
transport estimators is unclear. 
 
SIMULATION EXPERIMENT 
 We conducted a Monte Carlo simulation experiment to examine the variable selection 
problem in transport estimators. Specifically, we explored how the inclusion of 5 different types 
of unnecessary variables (in addition to the MSTS) affect the bias, mean square error, and 
confidence interval coverage of the parametric g-formula transport estimator.38 We limit our 
experiment to only consider variables that are not on the causal path from the exposure to the 
outcome (ie. pre-treatment variables). 
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Classification of transport variables according to causal structure 
Figure 4.4 shows the 5 different variable types that might be unnecessarily included in 
an s-admissible set (Äpc). In this example, all variable types are subsets of the s-admissible set 
and are (by definition) not part of the =>?>; all types are mutually exclusive. The unnecessary 
variables are categorized according to their relationships to the selection nodes, outcome 
variable, and causal quantity conditional on a specific =>?>. Note that if a variable is not a 
cause of the outcome, it also cannot be a cause of Φ. Similarly, if a variable is a cause of Φ it 
must also be a cause of the outcome. 
 
1. )ç: differ in distribution between the source and target populations; cause the 
outcome; but do not affect Φ. 
2. )à: differ in distribution between the source and target populations and are not 
causes of the outcome. 
3. )Ç: do not differ between the source and target populations and cause Φ. 
4. )´: do not differ between the source and target populations; cause the outcome; but 
do not affect Φ. 
5. )ã: do not differ between the source and target populations and do not cause the 
outcome.  
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Simulation Experiments 
We generated data according to the following data-generating processes. The magnitude and 
likelihood of practical positivity violations was highest in data-generating model 3. 
 >	~	§LM(0.5) R	~	§LM(0.5) =>?>,AÆ,A¶	~	Ø(1 + 3>, N≤#) A≥,A¥	~	Ø(1, 1) Aµ	~	Ø(0, 1) õ	~	Ø(100 + 20R + 10(=>?>)R + 10(AÆ) + 10(A≥)R + 10(A¥), 5) 
 
Where for each data-generating model = = J: 
N≤# = ∑1 + 5>, J = 11 + 3>, J = 21 + >, J = 3  
Figure 4.4. Selection diagrams showing the 5 categories of unnecessary variables 
that may be included in an s-admissible set. pÄp is the minimally sufficient transport 
set. After conditioning on this set, )ç,)à,)Ç,)´, and )ã are all unnecessary to 
transport Φ across the populations. 
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We aim to transport the causal quantity Φ = x(õVjt) 	− x(õVjs) from the study 
population (> = 1) to the target population (> = 0). In all 3 data-generating models, the true 
value of Φ in the target population is 40 and the true value of Φ in the study population is 70.  
For each data-generating model, we simulated 5000 datasets with a total N=5000 (with 
approximately 50% in > = 1 and 50% in > = 0). For each dataset, we fit a parametric g-
computation transport estimator38 for each of the following transport adjustment sets: 
 
 
 
 
Transport Adjustment Set (Äpé) ?>t = {MSTS} ?>∫ = {MSTS,AÆ} ?>ª = {MSTS,A¶} ?>º = {MSTS,A≥} ?>Ω = {MSTS,A¥} ?>æ = {MSTS,Aµ} ?>ø = {MSTS,AÆ,A¶} ?>¿ = {MSTS,AÆ,A≥,A¥} ?>¡ = {MSTS,A≥,A¥} ?>ts = {MSTS,AÆ,A¶,A≥,A¥,Aµ} ?>tt = {A≥} 
 
Table 4.2. List of transport adjustment sets used with the parametric g-formula transport 
estimator for each simulation. ?>ø includes any variables that differ between the two 
populations; ?>¿ includes all causes of Y; ?>¡ includes the =>?> and all causes of Y that 
don’t differ between the two populations; ?>ts includes the full set of variables; and ?>tt 
does not meet the s-admissibility criterion and serves as a negative control.  
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To fit the g-formula transport estimators, we first fit a conditional linear regression in the 
source population (> = 1) regressing Y on Z and all variables in the transport set including all 
possible interaction terms. We then used this model to predict the values of Y in the target 
population setting R	 = 1 and R = 0 and calculated the difference in mean outcomes under each 
treatment assignment.38 We used a non-parametric bootstrap with 1000 bootstrap samples to 
estimate the standard error.87  
We report the estimated bias, variance, mean square error (MSE), and confidence 
interval coverage for each transport set. All analyses were conducted using R version 3.5.2.88 
 
RESULTS 
 Across all 3 data-generating models, all transport sets that included the =>?> (and 
therefore met the s-admissibility criterion) were unbiased (Table 4.3). However, using the =>?> 
alone was not the optimal transport set in terms of MSE; ?>¿ had the lowest MSE across all 
data-generating models. Among the s-admissible sets (all except ?>tt), ?>ª had the highest 
MSE in each of the 3 data-generating models.  
Excluding variables that were causes of the outcome but did not modify the causal quantity of 
interest (AÆ and A¥) did not negatively affect the bias of the estimators, and including 
unnecessary variables that were not causes of the outcome and that did not differ between the 
populations (Aµ) did not increase the MSE compared to the MSTS alone. 
Because of the smaller standard deviations for =>?>,AÆ,	and A¶ in data-generating model 3, 
this model was most likely to produce practical positivity violations. However, the parametric 
models in the estimators were correctly specified and could therefore accurately extrapolate 
beyond the bounds of the source data, so these practical positivity violations did not induce bias 
in the transport estimators. Additionally, because the standard errors were smaller in the source 
population in this data-generating model compared to models 1 and 2, the estimates were 
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generally more precise. However, the pattern of relative performance between the transport sets 
differed in this data generating model. ?>¿, which included all causes of Y but no other 
unnecessary variables, performed substantially better than the other transport sets, while ?>ª 
and ?>ø	had markedly higher MSEs. 
 
DISCUSSION 
 The impact of including unnecessary variables in the parametric g-formula transport 
estimator varies depending on the type of extraneous variable that is included. As expected, 
excluding variables that cause the outcome but don’t modify the causal quantity of interest does 
not increase bias. However, including all causes of the outcome—regardless of whether the 
variable modifies the causal quantity of interest or varies between the populations—improves 
the MSE by reducing the standard error. Additionally, including variables that differ between the 
populations but don’t cause the outcome tends to increase the MSE. 
There are several practical implications uncovered by this study. When faced with a 
variable selection problem for transport, it’s best to focus on including as many causes of the 
outcome as possible. This is perhaps counterintuitive. Obvious differences between source and 
target populations are often the impetus for applying transportability methods in the first place, 
and these types of differences are often easier to detect. However, the strategy of including all 
variables that differ between two populations increases the chance that some variables that are 
not causes of the outcome will be included in the transport set, and the inclusion of these 
variables will likely increase the MSE of the estimators.  
Because we intended to highlight the impact of including different types of extraneous 
variables for the most common types of transport questions researchers are likely to face, we 
restricted our experiment to only include data-generating models with selection nodes on pre-
treatment variables, and we only evaluated the parametric g-formula transport estimator. Other 
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commonly used transport estimators include the inverse odds of selection weights and doubly 
robust targeted maximum likelihood transport estimators. We expect to find similar patterns 
across the different estimators, but future work should explore variable selection under other 
data-generating conditions and with other estimation approaches.  
 Our simulation experiment also only included correctly specified parametric models in 
the g-formula transport estimators. As a result, the estimates were unbiased in spite of the 
practical positivity violations in data-generating model 3. If the models used in the estimators are 
not correctly specified, there is no guarantee that the estimates would be unbiased. 
Based on our findings, a potential practical approach to variable selection for 
transportability would be to use the study data alone to determine what variables should be 
measured in target populations to transport the results. For example, after completion of a trial, 
researchers could conduct a careful analysis to identify all the characteristics that modified the 
effect of interest. Researchers looking to transport the trial’s results to a specific target 
population would then know what characteristics they would need to measure to do so. So long 
as the study measured all effect modifiers, this approach would ensure that the s-admissibility 
criteria is met and that any unnecessary variables included transport set (because they don’t 
differ between the populations) would improve the precision of the estimates. Of course, trial 
results can only be transported if they enroll populations that are heterogeneous with respect to 
the effect modifiers and if all those effect modifiers are measured. Future work should explore 
data-driven approaches for identifying optimal transport sets to further improve the accuracy 
and precision of transport estimators. 
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CONCLUSIONS 
The three studies described within this dissertation demonstrate how causal 
transportability can improve how results of clinical trials are used to inform implementation of 
new interventions. The first study found that population compositional differences between 
transgender women and cisgender men in iPrEx were sufficient to explain differences in the 
effectiveness of randomization to the active arm of the trial. The second study demonstrated 
how to generate target-specific guidance about how best to implement new interventions by 
transporting subgroup analyses of randomized trials to each target population. The third study 
considered how best to select variables for transport estimators to maximize the performance of 
the parametric g-computation transport estimator.    
Overall, causal transportability theory provides a rigorous solution to a wide range of 
previously intractable problems surrounding external validity of studies. However, there are 
important challenges in implementing these methods. First, transportability requires individual-
level measurements of the transport adjustment set in both the study and target populations. 
This means that trials need to consider what characteristics are likely to impact the 
effectiveness of the intervention under study prior to collecting data. Additionally, it may require 
that these characteristics are measured in a representative sample of each target population. 
Another challenge in implementing transportability is that as time passes, it may become less 
possible to account for all the relevant differences between populations. This means that 
transporting results of a trial should occur as quickly as possible to maximize the chance that 
the s-admissibility criteria have been met. Overall, for transportability to be most useful, 
researchers need to plan on implementing these tools early in the design of the study so that 
they can be used as quickly as possible. 
In the pursuit of maximizing external validity, many researchers  have championed 
pragmatic trials as a means of evaluating the effectiveness of implementation strategies in usual 
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care settings.89 However, in the face of heterogeneous effects of implementations, the quest for 
a single effect that applies universally is hopeless even if the trial design conforms to all the 
established features of a pragmatic trial (e.g., no recruitment restrictions, flexible interventions). 
So, unless the trial population is a random sample of all future target populations (an 
implausible concept given that even in the same location, the data generating process may 
evolve over time), even results of pragmatic trials will need to be formally transported to produce 
evidence that is relevant for different settings (or the same setting in the future). However, to 
avoid altering standard care practices, pragmatic trials often minimize the number of 
measurements taken over the course of the study, but formal transport requires individual-level 
measurements of variables that modify the effectiveness of the implementation strategy. By 
minimizing the number of characteristics measured, pragmatic trials preclude the ability to 
transport their results to external settings and are undermining their own goals of generating 
study results that could be applied to a range of target populations. Instead, if the objective of 
pragmatic trials is to produce more generalizable knowledge, it is essential that these studies 
understand and measure the mechanisms and modifiers of the implementation strategies being 
evaluated. 
Overall, this dissertation demonstrates a few areas in which transportability can greatly 
improve implementation of new interventions. There remains much work to be done in this area, 
and future researchers should consider how the transportability framework might affect their 
approach to designing and analyzing randomized trials.  
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